2024-12-03744.95 MB149页
2024-07-19732.69 MB40页11
2024-07-1973544.06 KB160页8
2024-07-19736.42 MB38页23
2024-07-19735.35 MB51页11
2024-07-19733.69 MB61页18
2024-07-19734.06 MB76页7
GModelARTICLEINPRESSANORL-1081;No.ofPages6EuropeanAnnalsofOtorhinolaryngology,HeadandNeckdiseasesxxx(2020)xxx–xxxAvailableonlineatScienceDirectwww.sciencedirect.comOriginalarticleFrenchSocietyofENT(SFORL)guidelines.ManagementofacuteBell’spalsyM.Fieuxa,V.Franco-Vidalb,P.Devicc,F.Bricaired,A.Charpiote,V.Darrouzetb,L.Denoixa,P.Gatignolf,N.Guevarag,M.Montavah,J.A.Rochi,F.Tankéréf,S.Tronchej,F.V... 2024-07-2173739.54 KB6页19
2024-07-2173154.81 KB1页14
2024-07-26734.17 MB15页
2024-07-267313.02 MB57页
2024-07-267313.69 MB41页
2024-07-3073101.69 MB401页
2024-07-31736.54 MB44页
2024-07-317314.85 KB2页
2024-07-317337.5 KB2页4
2024-08-12731.99 MB53页
2024-08-12731.26 MB24页
The 52nd edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information, spiral-bound and printed in a larger font (approximately 8pt) for ease of use. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians. Coverage includes: Clinical syndromes (pathogens, bacterial, fungal, mycobacterial, parasitic viral), Anti-infective agents (dosing, pediatric adjustments, renal adjustments, adverse effects, activity, pharmacology, drug-drug interactions), Preventative therapy. What's new in 2022: Numerous changes throughout, with major changes in the following areas: New Drugs - Addition of new COVID-19 drugs, cefiderocol, ibrexafungerp, brincidofovir, cabotegravir, doravirine, and more. New Tables - ECMO Drug Dos 2025-04-177332.87 MB324页
2025-05-127378.46 MB216页
